title: Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
abstract: A pilot trial was initiated for chronic myeloid leukaemia patients, which employed imatinib for remission induction, followed by reduced-intensity conditioning and an in vivo T-cell depleted graft. Out of nine patients, six experienced a molecular relapse and one patient had a haematological relapse at a median interval of 5 months after transplantation. Five relapsing patients achieved a 2nd molecular remission after treatment with either donor lymphocyte infusions (n = 4) or imatinib (n = 1). Two of nine patients died due to infectious complications. The probability of survival 2 years after transplant was 74% (95% CI 42-100%).
authors.affiliation: Third Department of Medicine, University Hospital of Ulm, Ulm, Germany.
authors.forename: Mark
authors.initials: M
authors.lastname: Ringhoffer
authors.forename: Stephanie von
authors.initials: Sv
authors.lastname: Harsdorf
authors.forename: Michael
authors.initials: M
authors.lastname: Schmitt
authors.forename: Markus
authors.initials: M
authors.lastname: Wiesneth
authors.forename: Thorsten
authors.initials: T
authors.lastname: Zenz
authors.forename: Stephan
authors.initials: S
authors.lastname: Stilgenbauer
authors.forename: Jochen
authors.initials: J
authors.lastname: Greiner
authors.forename: Konstanze
authors.initials: K
authors.lastname: Döhner
authors.forename: Martin
authors.initials: M
authors.lastname: Marx
authors.forename: Hartmut
authors.initials: H
authors.lastname: Döhner
authors.forename: Donald
authors.initials: D
authors.lastname: Bunjes
mesh_terms: D000328:Adult; D001549:Benzamides; D005260:Female; D016044:Fusion Proteins, bcr-abl; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D008212:Lymphocyte Depletion / Q000379:methods*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D010865:Pilot Projects; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012008:Recurrence; D012306:Risk; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
chemical_list: D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl